Copy Number Networks to Guide Combinatorial Therapy of Cancer and Proliferative Disorders

In a survival network for glioblastoma, we found that the epidermal growth factor receptor oncogene interacted with 46 genes

Andy Lin; Desmond J. Smith


Scholarcy highlights

  • New drug discovery is confronted by rising costs and diminishing success rates
  • A survival network for glioblastoma multiforme at single gene resolution We explored the existence of survival networks in cancer
  • We focus on the single gene resolution copy number alterations networks deduced from the radiation hybrid and glioblastoma datasets
  • A total of 46 genes were identified that interacted with epidermal growth factor receptor in the combined glioblastoma/RH survival network, of which 10 happened to be targets for existing drugs
  • SLC2A9 is a high capacity urate transporter and is inhibited by the uricosuric agent benzbromarone which is used to treat gout. These observations suggest that a flank attack strategy which strikes at both EGFR and its partner genes in the glioblastoma survival network may be an effective approach for treatment of these tumors
  • An example of one such pathway in the RH survival network ends on the EGFR oncogene. A total of 22 genes interacted with the EGFR gene in the RH network, of which seven happened to be targets for existing compounds
  • The strategy of copy number alterations network guided combinatorial therapy promises to be a useful approach to advancing novel treatments for a wide variety of common and uncommon disorders

Need more features? Save interactive summary cards to your Scholarcy Library.